Overview

CytoSorbents Investor Relations

Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world

Featured News

CytoSorbents

Press Release

21 Mar '25

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 21, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ... CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

04 Mar '25

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ... CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

26 Feb '25

CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2024 financial results and recent business highlights after the market close on Thursday, March 6, 2025. CytoSorbents’ ... CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

25 Feb '25

CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants

1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today the Company received aggregate gross ... CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants

View All News